BackAutolus Therapeutics plc Overview

Autolus Therapeutics plc Receivables

Track Autolus Therapeutics plc's receivables ($44M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$44.39M
43.52% YoYΔ $-34.20M vs prior year quarter

Peer trimmed avg / median

Loading

Autolus Therapeutics plc Receivables History

Loading

Autolus Therapeutics plc vs. peers: Receivables Comparison

Loading

Autolus Therapeutics plc Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Autolus Therapeutics plc (AUTL) FAQ

As of the most recent data (June 2026), AUTL shows a receivables of $44M. That compares with $79M in the prior-year period — down 43.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AUTL's receivables is now $44M (was $79M) — a 43.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Autolus Therapeutics plc is outperforming or lagging.

Tracking AUTL's receivables over time shows whether Autolus Therapeutics plc is scaling, shrinking, or reshaping that part of the business. The current reading is $44M That compares with $79M in the prior-year period — down 43.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Autolus Therapeutics plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $44M) with ownership activity and broader fundamentals.

Autolus Therapeutics plc's receivables is $44M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.